Skip to content
10-Q

Quarterly Report

Progenics Pharmaceuticals Inc

0001437749-20-009815

← back to feed
Filed
May 7, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · May 4, 2020 86.6M sh
Capex Q1 2020 · Mar 31, 2020 $3.55M
Capex Q1 2020 · Mar 31, 2019 $491K
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$7.61M
Operating Cash Flow Q1 2020 · Mar 31, 2019 −$18.52M
Long Term Debt Q1 2020 · Mar 31, 2020 $30.17M
Long Term Debt Q1 2020 · Dec 31, 2019 $31.91M
Short Term Debt Q1 2020 · Mar 31, 2020 $7.24M
Short Term Debt Q1 2020 · Dec 31, 2019 $7.12M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $29.53M
Cash And Equivalents Q1 2020 · Dec 31, 2019 $42.05M
Cash And Equivalents Q1 2020 · Mar 31, 2019 $109.59M
Cash And Equivalents Q1 2020 · Dec 31, 2018 $137.69M
Stockholders Equity Q1 2020 · Mar 31, 2020 $30.61M
Stockholders Equity Q1 2020 · Dec 31, 2019 $46.55M
Stockholders Equity Q1 2020 · Mar 31, 2019 $83.38M
Stockholders Equity Q1 2020 · Dec 31, 2018 $101.08M
Current Liabilities Q1 2020 · Mar 31, 2020 $19.1M
Current Liabilities Q1 2020 · Dec 31, 2019 $22.07M
Total Liabilities Q1 2020 · Mar 31, 2020 $67.73M
Total Liabilities Q1 2020 · Dec 31, 2019 $72.92M
Current Assets Q1 2020 · Mar 31, 2020 $40.55M
Current Assets Q1 2020 · Dec 31, 2019 $63.73M
Total Assets Q1 2020 · Mar 31, 2020 $98.34M
Total Assets Q1 2020 · Dec 31, 2019 $119.47M
Sga Expense Q1 2020 · Mar 31, 2020 $10.51M
Sga Expense Q1 2020 · Mar 31, 2019 $9.22M
Rd Expense Q1 2020 · Mar 31, 2020 $10.37M
Rd Expense Q1 2020 · Mar 31, 2019 $12.39M
Net Income Q1 2020 · Mar 31, 2020 −$16.8M
Net Income Q1 2020 · Mar 31, 2019 −$18.74M
Operating Income Q1 2020 · Mar 31, 2020 −$15.89M
Operating Income Q1 2020 · Mar 31, 2019 −$18.24M
Cost Of Revenue Q1 2020 · Mar 31, 2020 $1.56M